The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy
Cancer Biomarkers · 2025
DOI: 10.1177/18758592251343041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2025. Verfasst von Zihan Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Hypopharyngeal Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Higher Educational Institutions Youth Innovation Science and Technology Support Program of Shandong Province, National Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Purpose
The aim of this study was to evaluate the concentration of soluble programmed cell death ligand-1 (sPD-L1) in the plasma of hypopharyngeal squamous cell carcinoma (HSCC) patients before and after radiotherapy (RT) and to explore its correlation with prognosis.
Methods
A total of 47 patients and 12 healthy individuals were enrolled. All blood samples were collected before RT and 35 blood samples were obtained after RT. Twenty-three matched Formalin-fixed paraffin-embedding (FFPE) specimen from patient tumor biopsies were examined PD-L1 immunohistochemistry, and the sPD-L1 levels were quantified by enzyme-linked immunosorbent assay (ELISA).
Results
The level of plasma sPD-L1 in patients were higher than healthy individuals. Plasma sPD-L1 level at diagnosis correlated positively with T stage. The plasma sPD-L1 concentration had moderate correlations with PD-L1 expression in tissue (tPD-L1). In addition, the study proved that patients with high sPD-L1 had significantly worse overall survival (OS) than patients with low sPD-L1. sPD-L1 levels before RT was the unique independent prognostic factors for OS.
Conclusions
The study reported that sPD-L1 concentration before RT is proportional to the expression of tPD-L1. Besides, sPD-L1 before RT and tPD-L1 may serve as useful biomarkers for prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Oncology, Jining Tumor Hospital, Jining, Shandong, China.
Förderung
- National Natural Science Foundation of China
- Higher Educational Institutions Youth Innovation Science and Technology Support Program of Shandong Province
- National Natural Science Foundation of Shandong Province
- Science Technology Program of Jinan
- China Postdoctoral Science Foundation
Zitieren
APA
Zhou, Z., Ding, X., Bai, X., Yang, J., Xu, J., Xu, J., Chen, Y., Jiang, S., & Hu, M. (2025). The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy. Cancer Biomarkers. https://doi.org/10.1177/18758592251343041
Vancouver
Zhou Z, Ding X, Bai X, Yang J, Xu J, Xu J, et al. The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy. Cancer Biomarkers. 2025. doi:10.1177/18758592251343041
BibTeX
@article{Zhou2025,
author = {Zhou, Zihan and Ding, Xingchen and Bai, Xinbin and Yang, Jia and Xu, Jin and Xu, Juan and Chen, Yunhao and Jiang, Shumei and Hu, Man},
title = {The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy},
journal = {Cancer Biomarkers},
year = {2025},
doi = {10.1177/18758592251343041}
}
EUVIMED